Tonix Pharmaceuticals Holding Stock Analysis

TNXP Stock  USD 20.17  8.59  29.87%   
Tonix Pharmaceuticals Holding is overvalued with Real Value of 12.8 and Target Price of 5.83. The main objective of Tonix Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Tonix Pharmaceuticals Holding is worth, separate from its market price. There are two main types of Tonix Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Tonix Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tonix Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Tonix Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tonix Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Tonix Stock Analysis Notes

The company has price-to-book ratio of 1.33. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tonix Pharmaceuticals recorded a loss per share of 8039.0. The entity last dividend was issued on the 1st of November 2019. The firm had 1:100 split on the 5th of February 2025. Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people. To find out more about Tonix Pharmaceuticals Holding contact the company at 862 799 8599 or learn more at https://www.tonixpharma.com.

Tonix Pharmaceuticals Investment Alerts

Tonix Pharmaceuticals had very high historical volatility over the last 90 days
Tonix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (130.04 M) with profit before overhead, payroll, taxes, and interest of 2.34 M.
Tonix Pharmaceuticals Holding currently holds about 145.48 M in cash with (60.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38.
Tonix Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Latest headline from gurufocus.com: Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to ...

Tonix Pharmaceuticals Upcoming and Recent Events

11th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Tonix Largest EPS Surprises

Earnings surprises can significantly impact Tonix Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-13
2024-03-31-0.39-0.180.2153 
2022-08-08
2022-06-30-1.44-1.220.2215 
2023-03-13
2022-12-31-0.86-0.560.334 
View All Earnings Estimates

Tonix Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Tonix Pharmaceuticals' ESG score is a quantitative measure that evaluates Tonix Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Tonix Pharmaceuticals' operations that may have significant financial implications and affect Tonix Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Tonix Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Kellett Schaffner Wealth Advisors Llc2024-12-31
30 K
Ballew Advisors, Inc2024-12-31
25 K
Joseph P. Lucia & Associates, Llc2024-12-31
20 K
Morgan Stanley - Brokerage Accounts2024-12-31
18.3 K
Jpmorgan Chase & Co2024-12-31
17.3 K
Lpl Financial Corp2024-12-31
15 K
Wealthcare Advisory Partners Llc2024-12-31
10 K
Mrp Capital Investments Llc2024-12-31
10 K
Sbi Securities Co Ltd2024-12-31
3.8 K
Blackrock Inc2024-12-31
5.9 M
Geode Capital Management, Llc2024-12-31
M
Note, although Tonix Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tonix Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.01 M.

Tonix Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.80)(0.84)
Return On Capital Employed(0.95)(0.99)
Return On Assets(0.80)(0.84)
Return On Equity(0.93)(0.98)

Management Efficiency

Tonix Pharmaceuticals has return on total asset (ROA) of (0.4407) % which means that it has lost $0.4407 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3869) %, meaning that it created substantial loss on money invested by shareholders. Tonix Pharmaceuticals' management efficiency ratios could be used to measure how well Tonix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2025, Return On Tangible Assets is likely to drop to -0.84. In addition to that, Return On Capital Employed is likely to drop to -0.99. At this time, Tonix Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 03/28/2025, Liabilities And Stockholders Equity is likely to grow to about 171 M, while Non Current Liabilities Total is likely to drop slightly above 3 M.
Last ReportedProjected for Next Year
Book Value Per Share 189.53  199.01 
Tangible Book Value Per Share 189.37  198.83 
Enterprise Value Over EBITDA 0.93  0.97 
Price Book Value Ratio 0.17  0.18 
Enterprise Value Multiple 0.93  0.97 
Price Fair Value 0.17  0.18 
Enterprise Value-66.4 M-63.1 M
The management strategies employed by Tonix Pharmaceuticals' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Operating Margin
(5.51)
Beta
2.238
Return On Assets
(0.44)
Return On Equity
(1.39)

Technical Drivers

As of the 28th of March, Tonix Pharmaceuticals has the Semi Deviation of 13.64, coefficient of variation of 1609.01, and Risk Adjusted Performance of 0.0613. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tonix Pharmaceuticals, as well as the relationship between them.

Tonix Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tonix Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tonix Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Tonix Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tonix Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tonix Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tonix Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Stillwell Richard Newcomb over a week ago
Disposition of 83000 shares by Stillwell Richard Newcomb of Tonix Pharmaceuticals at 0.562 subject to Rule 16b-3
 
Fogarty Siobhan over three weeks ago
Insider Trading
 
Fogarty Siobhan over a month ago
Acquisition by Fogarty Siobhan of 13500 shares of Tonix Pharmaceuticals at 10.0625 subject to Rule 16b-3
 
Fogarty Siobhan over a month ago
Insider Trading
 
Fogarty Siobhan over a month ago
Insider Trading
 
Fogarty Siobhan over a month ago
Insider Trading
 
Fogarty Siobhan over a month ago
Insider Trading
 
Fogarty Siobhan over a month ago
Insider Trading
 
Fogarty Siobhan over a month ago
Insider Trading
 
Saenger Bradley over a month ago
Acquisition by Saenger Bradley of 540000 shares of Tonix Pharmaceuticals at 1.53 subject to Rule 16b-3
 
Sullivan Gregory M over three months ago
Acquisition by Sullivan Gregory M of 1250000 shares of Tonix Pharmaceuticals at 0.414 subject to Rule 16b-3
 
Olukotun Adeoye Y over three months ago
Acquisition by Olukotun Adeoye Y of 60000 shares of Tonix Pharmaceuticals at 0.509 subject to Rule 16b-3

Tonix Pharmaceuticals Outstanding Bonds

Tonix Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tonix Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tonix bonds can be classified according to their maturity, which is the date when Tonix Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Tonix Pharmaceuticals Predictive Daily Indicators

Tonix Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tonix Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tonix Pharmaceuticals Corporate Filings

8K
24th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
21st of March 2025
Other Reports
ViewVerify
10K
18th of March 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
8K
10th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
4th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
28th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
27th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
21st of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Tonix Pharmaceuticals Forecast Models

Tonix Pharmaceuticals' time-series forecasting models are one of many Tonix Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tonix Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Tonix Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tonix Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tonix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tonix Pharmaceuticals. By using and applying Tonix Stock analysis, traders can create a robust methodology for identifying Tonix entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(12.88)(13.53)
Operating Profit Margin(13.54)(14.22)
Net Loss(12.88)(13.53)
Gross Profit Margin 0.23  0.34 

Current Tonix Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tonix analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tonix analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.83Strong Buy2Odds
Tonix Pharmaceuticals Holding current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Tonix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tonix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tonix Pharmaceuticals, talking to its executives and customers, or listening to Tonix conference calls.
Tonix Analyst Advice Details

Tonix Stock Analysis Indicators

Tonix Pharmaceuticals Holding stock analysis indicators help investors evaluate how Tonix Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tonix Pharmaceuticals shares will generate the highest return on investment. By understating and applying Tonix Pharmaceuticals stock analysis, traders can identify Tonix Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow25.8 M
Long Term Debt4.7 M
Common Stock Shares Outstanding736.3 K
Total Stockholder Equity139.6 M
Property Plant And Equipment Net42.8 M
Cash And Short Term Investments98.8 M
Cash98.8 M
Accounts Payable4.5 M
Net Debt-90.7 M
50 Day M A19.7134
Total Current Liabilities18.3 M
Other Operating Expenses146.8 M
Non Current Assets Total43.9 M
Non Currrent Assets Other951 K
Stock Based Compensation4.8 M

Additional Tools for Tonix Stock Analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.